860808 | CP-LC-1401
2-butyloctyl 3-((4-((2-(dimethylamino)ethyl)amino)-3-(2-octyldodecanamido)-4-oxobutyl)thio)propanoate
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
CP-LC-1401
2-butyloctyl 3-((4-((2-(dimethylamino)ethyl)amino)-3-(2-octyldodecanamido)-4-oxobutyl)thio)propanoate
| Manufactured and Distributed under License from Certest Biotec S.L
CP-LC-1401 is an ionizable lipid that successfully encapsulates mRNA and CRISPR/Cas9. In vivo studies carried out in mice show that lipid nanoparticle (LNP) formulations using ionizable lipid CP-LC-1401 exhibit increased mRNA expression and improved delivery of CRISPR/Cas9 compared to industry leading formulations. LNP formulations using CP-LC-1401 also show favorable safety profiles and improved biodegradability compared to industry leading formulations. LNPs formulated with CP-LC-1401 have shown a primary biodistribution in the liver and exhibit high endosomal escape. |
| C43H85N3O4S |
Powered by Bioz
